Neurocrine Biosciences Stock Equity Positions Weight

NBIX Stock

USD 136.85 1.25 0.91%

Neurocrine Biosciences fundamentals help investors to digest information that contributes to Neurocrine Biosciences' financial success or failures. It also enables traders to predict the movement of Neurocrine Stock. The fundamental analysis module provides a way to measure Neurocrine Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurocrine Biosciences stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Neurocrine Biosciences Company Equity Positions Weight Analysis

Neurocrine Biosciences' Percentage of fund asset invested in equity instruments. About 80% of global funds and ETFs carry equity instruments on their balance sheet.

Stock Percentage

% of Equities

in the fund

More About Equity Positions Weight | All Equity Analysis

Neurocrine Equity Positions Weight Driver Correlations

Understanding the fundamental principles of building solid financial models for Neurocrine Biosciences is extremely important. It helps to project a fair market value of Neurocrine Stock properly, considering its historical fundamentals such as Equity Positions Weight. Since Neurocrine Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neurocrine Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neurocrine Biosciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Long Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Long Term Debt Total	Net Invested Capital	Short Long Term Debt	Net Working Capital	Capital Stock
Total Assets		0.99	0.45	0.57	0.99	0.98	0.97	0.99	0.58	0.89	0.95	0.77	0.57	0.89	0.83	0.96	0.83	0.54	0.98	-0.8	0.84	-0.73	0.81	0.92
Total Stockholder Equity	0.99		0.4	0.62	0.98	0.99	0.94	0.98	0.54	0.89	0.93	0.7	0.54	0.87	0.86	0.98	0.8	0.5	0.97	-0.84	0.83	-0.72	0.83	0.93
Net Debt	0.45	0.4		0.07	0.48	0.45	0.55	0.47	0.76	0.23	0.47	0.6	0.24	0.47	0.39	0.3	0.43	0.34	0.53	0.08	0.29	-0.23	0.08	0.25
Retained Earnings	0.57	0.62	0.07		0.63	0.65	0.43	0.5	0.13	0.57	0.41	0.08	-0.19	0.44	0.7	0.6	0.2	0.26	0.56	-0.69	0.56	-0.35	0.62	0.64
Accounts Payable	0.99	0.98	0.48	0.63		0.99	0.95	0.97	0.64	0.86	0.93	0.7	0.49	0.85	0.86	0.93	0.77	0.51	0.97	-0.78	0.86	-0.65	0.76	0.91
Net Receivables	0.98	0.99	0.45	0.65	0.99		0.92	0.97	0.59	0.86	0.93	0.67	0.49	0.84	0.91	0.95	0.76	0.48	0.96	-0.81	0.81	-0.67	0.81	0.91
Total Liab	0.97	0.94	0.55	0.43	0.95	0.92		0.97	0.66	0.86	0.94	0.88	0.6	0.91	0.73	0.89	0.85	0.6	0.96	-0.69	0.82	-0.73	0.72	0.86
Total Current Assets	0.99	0.98	0.47	0.5	0.97	0.97	0.97		0.62	0.88	0.98	0.81	0.62	0.91	0.83	0.96	0.86	0.57	0.95	-0.77	0.77	-0.75	0.8	0.89
Short Term Debt	0.58	0.54	0.76	0.13	0.64	0.59	0.66	0.62		0.42	0.68	0.65	0.38	0.6	0.42	0.41	0.55	0.43	0.57	-0.08	0.4	-0.17	0.14	0.42
Intangible Assets	0.89	0.89	0.23	0.57	0.86	0.86	0.86	0.88	0.42		0.83	0.69	0.5	0.9	0.69	0.91	0.75	0.64	0.82	-0.81	0.7	-0.79	0.82	0.86
Short Term Investments	0.95	0.93	0.47	0.41	0.93	0.93	0.94	0.98	0.68	0.83		0.82	0.64	0.88	0.77	0.89	0.86	0.59	0.89	-0.68	0.72	-0.74	0.74	0.83
Long Term Debt	0.77	0.7	0.6	0.08	0.7	0.67	0.88	0.81	0.65	0.69	0.82		0.65	0.85	0.43	0.68	0.84	0.64	0.74	-0.4	0.53	-0.69	0.51	0.6
Common Stock	0.57	0.54	0.24	-0.19	0.49	0.49	0.6	0.62	0.38	0.5	0.64	0.65		0.61	0.29	0.58	0.87	0.46	0.51	-0.32	0.34	-0.56	0.55	0.51
Property Plant Equipment	0.89	0.87	0.47	0.44	0.85	0.84	0.91	0.91	0.6	0.9	0.88	0.85	0.61		0.6	0.88	0.88	0.71	0.83	-0.62	0.63	-0.8	0.72	0.77
Current Deferred Revenue	0.83	0.86	0.39	0.7	0.86	0.91	0.73	0.83	0.42	0.69	0.77	0.43	0.29	0.6		0.83	0.55	0.29	0.81	-0.75	0.63	-0.55	0.78	0.79
Net Tangible Assets	0.96	0.98	0.3	0.6	0.93	0.95	0.89	0.96	0.41	0.91	0.89	0.68	0.58	0.88	0.83		0.82	0.5	0.92	-0.88	0.75	-0.79	0.89	0.92
Capital Surpluse	0.83	0.8	0.43	0.2	0.77	0.76	0.85	0.86	0.55	0.75	0.86	0.84	0.87	0.88	0.55	0.82		0.66	0.78	-0.54	0.56	-0.74	0.74	0.75
Deferred Long Term Liab	0.54	0.5	0.34	0.26	0.51	0.48	0.6	0.57	0.43	0.64	0.59	0.64	0.46	0.71	0.29	0.5	0.66		0.47	-0.28	0.35	-0.61	0.52	0.5
Long Term Investments	0.98	0.97	0.53	0.56	0.97	0.96	0.96	0.95	0.57	0.82	0.89	0.74	0.51	0.83	0.81	0.92	0.78	0.47		-0.76	0.89	-0.67	0.74	0.89
Long Term Debt Total	-0.8	-0.84	0.08	-0.69	-0.78	-0.81	-0.69	-0.77	-0.08	-0.81	-0.68	-0.4	-0.32	-0.62	-0.75	-0.88	-0.54	-0.28	-0.76		-0.74	0.63	-0.84	-0.89
Net Invested Capital	0.84	0.83	0.29	0.56	0.86	0.81	0.82	0.77	0.4	0.7	0.72	0.53	0.34	0.63	0.63	0.75	0.56	0.35	0.89	-0.74		-0.53	0.61	0.82
Short Long Term Debt	-0.73	-0.72	-0.23	-0.35	-0.65	-0.67	-0.73	-0.75	-0.17	-0.79	-0.74	-0.69	-0.56	-0.8	-0.55	-0.79	-0.74	-0.61	-0.67	0.63	-0.53		-0.84	-0.68
Net Working Capital	0.81	0.83	0.08	0.62	0.76	0.81	0.72	0.8	0.14	0.82	0.74	0.51	0.55	0.72	0.78	0.89	0.74	0.52	0.74	-0.84	0.61	-0.84		0.85
Capital Stock	0.92	0.93	0.25	0.64	0.91	0.91	0.86	0.89	0.42	0.86	0.83	0.6	0.51	0.77	0.79	0.92	0.75	0.5	0.89	-0.89	0.82	-0.68	0.85

Click cells to compare fundamentals

Funds with most asset allocated to stocks can be subclassified into many different categories such as market capitalization or investment style.

Competition

Predict Neurocrine Biosciences

According to the company disclosure, Neurocrine Biosciences has an Equity Positions Weight of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Did you try this?

Run Portfolio Holdings Now

Portfolio Holdings

Check your current holdings and cash postion to detemine if your portfolio needs rebalancing

All Next

Launch Module

Neurocrine Biosciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Neurocrine Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Neurocrine Biosciences' managers, analysts, and investors.

Environmental

Governance

Social

Neurocrine Fundamentals

	Return On Equity	0.16
	Return On Asset	0.12
	Profit Margin	0.17 %
	Operating Margin	0.30 %
	Current Valuation	13.01 B
	Shares Outstanding	101.25 M
	Shares Owned By Insiders	0.99 %
	Shares Owned By Institutions	95.41 %
	Number Of Shares Shorted	3.39 M
	Price To Earning	202.90 X
	Price To Book	5.14 X
	Price To Sales	6.23 X
	Revenue	1.89 B
	Gross Profit	1 B
	EBITDA	358 M
	Net Income	249.7 M
	Cash And Equivalents	799.4 M
	Cash Per Share	8.31 X
	Total Debt	428.4 M
	Debt To Equity	0.18 %
	Current Ratio	2.48 X
	Book Value Per Share	26.87 X
	Cash Flow From Operations	389.9 M
	Short Ratio	3.86 X
	Earnings Per Share	3.76 X
	Price To Earnings To Growth	0.33 X
	Target Price	165.84
	Number Of Employees	1.7 K
	Beta	0.35
	Market Capitalization	13.98 B
	Total Asset	3.25 B
	Retained Earnings	(157.1 M)
	Working Capital	952.2 M
	Current Asset	384.07 M
	Current Liabilities	25.71 M
	Net Asset	3.25 B

About Neurocrine Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Neurocrine Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurocrine Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurocrine Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC